Last reviewed · How we verify
NCT04175067
Evaluation of Thiol Disulfide Balance in Stage 1 Endometrium Cancer
trial testing Disulphide(μmol/L) in Endometrium Cancer in 117 participants. Completed in 15 November 2019.
31 October 2019
Quick facts
| Lead sponsor | Muğla Sıtkı Koçman University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 117 |
| Start date | 1 August 2018 |
| Primary completion | 31 October 2019 |
| Estimated completion | 15 November 2019 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Disulphide(μmol/L)
- Total Oxidant Capacity(μmolH2O2Equiv/L)
Conditions studied
- Endometrium Cancer — all drugs for Endometrium Cancer →
- Oxidative Stress — all drugs for Oxidative Stress →
Sponsor
Muğla Sıtkı Koçman University
Who can join
18 and older, female only, with Endometrium Cancer or Oxidative Stress. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to investigate thiol-disulfide balance in early stage endometrium cancer patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Reactive oxygen species (ROS) in cancer: from mechanism to therapeutic implications.
Akter S, Madhuvilakku R, Kar AK, Nila IS, et al · · 2026 · PMID 41881983 · DOI 10.1038/s41392-026-02583-x
Verify or expand the search:
- PubMed search for NCT04175067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Disulphide(μmol/L)
Trials testing the same drug.
- NCT04177641 — Evaluation of Thioldisulfide Balance in Cervical Preinvasive Lesions · completed
- NCT04258553 — Thiol Disulfide Balance in Cervix Cancer · completed
Other recruiting trials for Endometrium Cancer
Currently open trials in the same condition.
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07318727 — Comparative Study on the Effect of Diet Interventions on Weight Loss in Overweight Endometrial Cancer Patients Undergoin · NA · recruiting
- NCT06841653 — A.I and Machine Learning Based Risk Prediction Model to Improve the Clinical Management of Endometrial Cancer. · recruiting
- NCT06169449 — Weight Management in Overweight Endometrial Cancer Patients Undergoing Fertility-sparing Treatment · NA · recruiting
- NCT04014530 — Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometria · Phase 1, PHASE2 · recruiting
Other Muğla Sıtkı Koçman University trials
Trials by the same sponsor.
- NCT05046834 — Effect of Cold Application on Patient's Pain and Vital Signs During Chest Tube Removal. · NA · withdrawn
- NCT07323160 — Determining the Effect of Education Given to Patients Undergoing Outpatient Anal Fistula Surgery · NA · not yet recruiting
- NCT07308730 — Pain Diary Use After Laparoscopic Cholecystectomy · NA · recruiting
- NCT06704399 — Psychoeducation Based on Acceptance and Commitment Therapy · NA · not yet recruiting
- NCT07183956 — Comparison of the Silverman-Andersen Score and the Downes Score · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04175067 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Muğla Sıtkı Koçman University
- Last refreshed: 22 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04175067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing